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ABSTRACT
Myelin sheath thickness is precisely adjusted to axon cali-
ber, and in the peripheral nervous system, neuregulin 1
(NRG1) type III is a key regulator of this process. It has
been proposed that the protease BACE1 activates NRG1 de-
pendent myelination. Here, we characterize the predicted
product of BACE1-mediated NRG1 type III processing in
transgenic mice. Neuronal overexpression of a NRG1 type
III-variant, designed to mimic prior cleavage in the juxta-
membrane stalk region, induces hypermyelination in vivo
and is sufﬁcient to restore myelination of NRG1 type III-de-
ﬁcient neurons. This observation implies that the NRG1
cytoplasmic domain is dispensable and that processed
NRG1 type III is sufﬁcient for all steps of myelination. Sur-
prisingly, transgenic neuronal overexpression of full-length
NRG1 type III promotes hypermyelination also in BACE1
null mutant mice. Moreover, NRG1 processing is impaired
but not abolished in BACE1 null mutants. Thus, BACE1 is
not essential for the activation of NRG1 type III to promote
myelination. Taken together, these ﬁndings suggest that
multiple neuronal proteases collectively regulate NRG1
processing. V V C 2011 Wiley Periodicals, Inc.
INTRODUCTION
Matching myelin sheath thickness to axon caliber is
critically important for optimal nerve impulse conduc-
tion and requires reciprocal signaling between axons
and glial cells. A key regulator of peripheral myelination
is the growth factor neuregulin (NRG) 1 type III (Birch-
meier and Nave, 2008; Nave and Salzer, 2006). This axo-
nal protein is not only required for embryonic develop-
ment of the Schwann cell lineage (Wolpowitz et al.,
2000) but also NRG1 type III regulates the ensheath-
ment fate of axons (Taveggia et al., 2005) and myelin
sheath thickness (Michailov et al., 2004).
NRG1 type III is a member of a large family of growth
and differentiation factors encoded by the single Nrg1
gene (Falls, 2003; Mei and Xiong, 2008). All NRG1 iso-
forms share an epidermal growth factor (EGF)-like
extracellular domain and activate receptor tyrosine
kinases of the ErbB family (Mei and Xiong, 2008).
NRG1 type III is characterized by a cysteine-rich
domain (CRD), which serves as a second N-terminal
transmembrane domain (Cabedo et al., 2002; Ho et al.,
1995; Schroering and Carey, 1998). Thus, its membrane
topology suggests a tight association of the signaling
domain with the cell membrane (Wang et al., 2001). The
identiﬁcation of truncated NRG1 isoforms in tissue
extracts has suggested that proteolytic processing of
full-length NRG1 isoforms regulates its functions (Jes-
sell et al., 1979; Lemke and Brockes, 1984). When ana-
lyzed in cultured cells, several proteases, including
ADAM19 (b-meltrin), TACE (ADAM17), and BACE1 (b-
site amyloid precursor protein–cleaving enzyme1), can
cleave the membrane-anchored forms of NRG1 type I
and II. By acting as ‘‘sheddases,’’ they release the EGF-
like domain (Horiuchi et al., 2005; Hu et al., 2008; Mon-
tero et al., 2000; Shirakabe et al., 2001; Willem et al.,
2006).
For ADAM19-deﬁcient mice, a delay of remyelination
after nerve crush has been documented, but the develop-
mental time course of myelination appears normal
(Wakatsuki et al., 2009). TACE cleaves recombinant
NRG1 within the EGF-like domain and reduces active
NRG1 type III on the axonal surface. Thus, inactivation
of TACE in spinal motor neurons causes hypermyelina-
tion in vivo (La Marca et al., 2011). In contrast, BACE1-
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V V C 2011 Wiley Periodicals, Inc.deﬁcient mice are hypomyelinated in the PNS (Willem
et al., 2006) and accumulate full-length NRG1 isoform(s)
in the brain. Finally, mouse mutants lacking the zinc
peptidase nardilysin, an upstream activator of both
TACE and BACE1, exhibit also peripheral hypomyelina-
tion (Ohno et al., 2009), with a similar accumulation of
full-length NRG1 in the brain. Thus, processing of
NRG1 type III in peripheral nerves could be part of an
activation step that is critical for axon-glia signaling.
Collectively, these data suggest a working model in
which BACE1 activates axonal NRG1 type III, which
subsequently stimulates Schwann cells to make myelin.
In this study, we explored NRG1 type III processing
and the functional interaction between NRG1 type III
and BACE1 during myelination in vivo. NRG1 process-
ing is reduced but not abolished in the absence of
BACE1, and neuronal overexpression of full-length
NRG1 type III promotes hypermyelination also in
BACE1 null mutant mice. This suggests a revised model
in which multiple proteases collectively regulate NRG1
type III during myelination in vivo.
MATERIALS AND METHODS
Transgenic Constructs
HA-NRG1
FL was generated by PCR from murine
NRG1 type IIIb1a cDNA (kindly provided by C. Lai),
which added two consecutive hemagglutinin (HA) pep-
tide tags to the N-terminus. HA-NRG1
GIEF was gener-
ated by PCR from HA-NRG1
FL cDNA by introducing a
stop codon after the ‘‘GIEF’’ coding sequence. Primer
sequences are available upon request. PCR products
were veriﬁed by DNA sequencing. Both HA-NRG1
FL and
HA-NRG1
GIEF cDNAs were subcloned into the XhoI site
of the Thy1.2 expression cassette (Caroni, 1997).
Mouse Lines
To generate HA-NRG1
FL and HA-NRG1
GIEF trans-
genic mouse lines, the corresponding Thy1.2 expression
cassettes were excised from the plasmid backbone by
PvuI/NotI digest and injected into fertilized FVB (HA-
NRG1
FL) or C57BL/6 (HA-NRG1
GIEF) mouse oocytes.
One founder each was used to establish HA-NRG1
FL
and HA-NRG1
GIEF mouse lines. Transgenic line HA-
NRG1
FL was backcrossed to C57BL/6 for more than 10
generations. BACE1 mutants (Cai et al., 2001) were pur-
chased from Jackson Laboratory. Genotyping primer
sequences are available upon request. All mouse experi-
ments were performed in compliance with animal poli-
cies approved by the State of Lower Saxony.
RNA Expression Analysis
RNA isolation was performed using the RNeasy Mini
Prep kit (Qiagen). cDNAwas synthesized from 500 ng RNA
using random nonamers and Superscript III Reverse Tran-
scriptase (Invitrogen). RT-PCR to verify transgene expres-
sion was performed using primers: (forward) 50-GGTGCAG
CAACTGGAGG CGTTG-30 and (reverse) 50-GTCCACAAA
TACCCACTTTAGGCCAGC-30. Tubulin was ampliﬁed with
primers (forward) 50-GATATCGCTGCGCTGGTCGTC-30
and (reverse) 50-CATGGCTGGGGTGTTGAAGGTC-30.
Cell Culture and Immunoblotting
HEK293T cells were grown on poly-L-lysine (PLL)
coated culture dishes and transfected using Lipofect-
amine 2000 (Invitrogen) at 70% conﬂuency. The follow-
ing plasmids were used for transfections: pCMV2-HA-
NRG1
FL, pCMV2-HA-NRG1
GIEF, and pcDNA3.1-BACE1
(Westmeyer et al., 2004). Protease inhibitor b-secretase
inhibitor IV (2 lM; Calbiochem) was added 2 h after
transfection. Protein lysates were prepared 24 h after
transfection with RIPA buffer supplemented with prote-
ase inhibitors (Complete mini, Roche). A total of 10 lgo f
protein lysates was used for Western blotting.
Split-TEV Assay
Split-TEV assays for the analysis of protein–protein
interactions at the cell surface were performed essen-
tially as described (Wehr et al., 2006). Brieﬂy, NRG1
constructs (pCMV2-HA-NRG1
FL, pCMV2-HA-NRG1
GIEF)
were transfected into PC12 cells by lipofection (Lipofec-
tamin 2000; Invitrogen). NRG1-transfected cells were
added to PC12 cells expressing ErbB2 and ErbB3 recep-
tor variants fused to inactive N- (ErbB2N-TEV) and
C-terminal (ErbB3-C-TEV) fragments of the tobacco etch
virus (TEV) protease. ErbB2N-TEV is additionally fused
to a transcription factor (GV) through the TEV protease
cleavable peptide sequence tevS (ErbB2N-TEV-tevS-GV).
NRG1-mediated ErbB receptor dimerization brings the
two inactive TEV protease fragments in close proximity,
which reconstitutes protease activity, and activates lucif-
erase reporter gene through GV release. Luciferase ac-
tivity was measured using the Mithras LB 940 Plate
Reader (Bertholde). Results were displayed as relative
luminescence units (RLUs). A one-sided Student’s t-test
was used for statistical analysis.
Dissociated Dorsal Root Ganglia Explants
Dorsal root ganglia (DRG) were dissected from C57Bl/6
mouse embryos at E13 as described (Saher et al., 2009).
Brieﬂy, dissected DRG were triturated in 0.25% trypsin at
37C. Cells were plated onto collagen-coated 18-mm cover-
slips and maintained in MEM1L-glutamine media supple-
mented with 10% FBS and 50 ng/ll 2.5S nerve growth fac-
tor (NGF) (Alomone Labs). Myelination was induced after
1 week by supplementing medium with 50 lg/ml ascorbic
acid (Sigma). Myelinating growth medium was changed
every 2nd day. Treatment with 2 lM b-secretase inhibitor
IV and 1 lM ADAM’s protease inhibitor GM6001 (Calbio-
chem) were initiated 2 days before induction of myelina-
204 VELANAC ET AL.
GLIAtion. Protease inhibitors were added freshly in myelinat-
ing growth medium. Control coverslips were treated with
with dimethyl-sulfoxide (DMSO). Cultures were analyzed 7
or 14 days after induction of myelination by immunostain-
ing for MBP and tubulin. Brieﬂy, cells were ﬁxed for 10 min
in 4% PFA in phosphate buffer (PB), permeabilized 5 min
at 220C with ice-cold methanol, and blocked for 1 h in 3%
BSA in PBS. Primary antibodies were incubated overnight
in blocking solution at RT. Secondary antibodies and DAPI
(1:2000) in blocking solution were applied for 1 h at RT.
Antibodies: rabbit anti-MBP (1:200; DAKO), mouse Tuj1
(1:500; Covance), anti-rabbit IgG-cy2 (1:100; Dianaova),
and anti-mouse IgG-cy3 (1:1000; Dianova). Quantiﬁed
numbers of myelin segments and nuclei were statistically
analyzed using one-sided Student’s t-test.
DRG-Schwann Cell Co-cultures
DRG neurons were prepared from E14 wildtype or
NRG1 type III-speciﬁc (CRD2/2) null mutant embryos
(Wolpowitz et al., 2000). Selection of sensory neurons by
cycles of 5-ﬂuorodeoxyuridine (FDUR) treatment, prepa-
ration, and addition of rat Schwann cells to the estab-
lished DRG neuron culture was essentially as described
(Taveggia et al., 2005). Myelination was initiated by
addition of ascorbic acid to media (50 lg/mL) 2 days af-
ter addition of rat Schwann cells. Myelination was
assessed by immunostaining for MBP-positive myelin
segments 1 or 2 weeks after myelination induction. Anti-
bodies: mouse anti-MBP (1:250; Sternberger Monoclonal)
and chicken anti-NF (1:2000; Covance). For Western
blotting, co-cultures lysed in lysis buffer (95 mM NaCl,
25 mM Tris pH 7.5, 10 mM EDTA, 2% SDS, 1 mM NaF,
1m MN a 3VO4, 1% protease inhibitor), 12 days after
myelination induction. Membranes were probed with
mouse anti-MBP (1:4000; Sternberger Monoclonal) and
rabbit anti-actin (1:4000; Sigma).
Generation of Lentiviruses and Infection
of DRG Neurons
HA-NRG1
FL and HA-NRG1
GIEF cDNAs were sub-
cloned into pLenti6/V5-DEST for lentiviral expression by
gateway cloning. Primer sequences are available upon
request. Lentiviruses expressing HA-NRG1
FL and HA-
NRG1
GIEF were generated using the ViraPower Lentivi-
ral Expression System (Invitrogen) as described
(Taveggia et al., 2005). For viral infection, cultures were
incubated with viral supernatants in DRG culture media
for 16 h immediately after dissection. Viral expression
was conﬁrmed by anti-HA staining 11 days postinfection
using rabbit anti-HA antibody (1:100; Sigma).
Protein Analysis
Tissues were homogenized in RIPA buffer supple-
mented with protease inhibitors (Complete mini, Roche).
Protein concentrations were determined using the Bio-
Rad DC protein assay. Typically, 30–40 lg of protein
lysates was separated by SDS-PAGE electrophoresis and
transferred onto PVDF membranes (Amersham-Hybond
P). Membranes were blocked in TBST (TBS/
0.05%Tween) with 5% milk and incubated over night
with primary antibody at 4C. After washing in TBST,
membranes were incubated with appropriate HRP-con-
jugated secondary antibodies for 1 h at RT and devel-
oped using the ECL plus detection kit (Perkin Elmer
Life Sciences). The following primary antibodies were
used: rat anti-HA tag antibody (1:1000; Roche), rabbit
anti-carboxy terminus of neuregulin1 (1:500, Santa Cruz
sc-348), rat anti-GIEF (1:50; clone 4F10; Michael Willem
unpublished), rabbit anti-Necl1 (1:1000; gift from Elior
Peles), and mouse anti-a-tubulin (1:2000; Sigma). HRP-
conjugated secondary antibodies (Dianova) were used at
1:5000 dilution. Western blot quantiﬁcation was per-
formed using ImageJ software. Values were normalized
to tubulin. A two-sided Student’s t-test was used for sta-
tistical analysis.
Histology and Immunohistochemistry
Mice were anesthetized with avertin (0.2 mL/10 g)
and perfused with 4% PFA in 0.1 M PB. Dissected tissue
was postﬁxed overnight at 4C and embedded in para-
plast. 5 lm thick microtome sections was subjected to
histological analysis. For ﬂuorescent immunostaining,
sections were blocked with 20% goat serum in PBS/BSA,
incubated with primary antibodies overnight at 4C, fol-
lowed by incubation with the corresponding cy2 (1:100;
Dianova) or cy3 (1:1000; Dianova) coupled secondary
antibodies for 1 h at RT. The following primary antibod-
ies were used: mouse anti-HA tag (1:250; Covance), rab-
bit anti-carboxy terminus of neuregulin1 (1:100; Santa
Cruz sc-348), rabbit anti-neuroﬁlament 200 (1:200;
Sigma), rabbit anti-peripherin (1:500; Chemicon), mouse
anti-class III b-tubulin (1:250; Covance), mouse anti-
NeuN (1:100; Chemicon), rabbit anti-parvalbumin
(1:200, Swant), rabbit anti-Olig2 (1:100; gift from John
Alberta), and rabbit anti-Necl1 (1:1000; gift from Elior
Peles). Nuclei were counterstained with DAPI (1:2000).
Images of ﬂuorescently labeled tissue were obtained
with a SP2-AOBS Leica confocal microscope and proc-
essed using Photoshop CS3 and ImageJ software.
Electron Microscopy and Morphological Analysis
Mice were transcardially perfused with Karlsson and
Schulz ﬁxative (2.5% glutaraldehyde and 4% PFA in
PB). Dissected sciatic nerves were embedded in epoxy
resin. Semithin sciatic nerve cross sections (0.5 lm)
were cut on a microtome (Ultracut S, Leica) with a dia-
mond knife (Diatome Histo 45) and stained for light mi-
croscopy with Methylenblue-Azur II for 1 min at 60C.
Ultrathin sections (50 nm) for electron microscopy were
cut with a diamond knife (Diatome Ultra 35) placed on
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Formvar polyvinyl and contrasted. For g-ratio measure-
ment and quantiﬁcation of axon and Schwann cell num-
bers images were obtained with the DMRXA (Leica)
microscope with a Kappa DX20 H-FW digital camera.
G-ratios of at least 100 myelinated axons per mouse
were measured using the ImageJ g-ratio plug-in. For
ultrastructural analysis, sections were imaged using a
LEO EM912 Omega electron microscope (Zeiss) with an
on-axis 2048 3 2048-CCD camera (Proscan). All images
were processed using Photoshop CS3 and ImageJ soft-
ware. For statistical analysis of the quantiﬁcations a
one-sided Student’s t-test was used.
Immuno-EM
For immunoelectron microscopy, mice were transcar-
dially perfused with 0.2% glutaraldehyde and 4% PFA in
0.1 M PB. Small pieces of the cortex were incubated in
2.3 M sucrose in 0.1 M PB overnight. Tissue blocks were
mounted onto aluminum pins for ultramicrotomy and
frozen in liquid nitrogen. Ultrathin cryosections were cut
with a diamond knife (Diatome) at 2110C using a cryo-
ultramicrotome UC6 (Leica) and picked up in a 1:1 mix-
ture of 2% methylcellulose and 2.3 M sucrose. Thawed
sections were immunolabeled as described (Peters and
Pierson, 2008). For double-immunolabeling, sections
were incubated with a polyclonal antibody directed
against PSD95 (Fukaya and Watanabe, 2000), followed
by protein A gold conjugate (15 nm) purchased from the
Cell Microscopy Center, Department of Cell Biology, Uni-
versity Medical Center Utrecht, The Netherlands. Next,
a monoclonal mouse anti-HA antibody (Covance) was
used as primary antibody followed by incubation with a
secondary rabbit antibody directed against mouse IgG
(Rockland) and a protein A gold conjugate (10 nm).
RESULTS
Proteolytic Cleavage of NRG1 type III in the
Juxtamembrane ‘‘Stalk’’ Region Activates a
Myelination Signal
Several proteases have been implicated in NRG1 proc-
essing (Hu et al., 2008; La Marca et al., 2011; Montero
et al., 2000; Wakatsuki et al., 2009; Werner et al., 2008;
Willem et al., 2006). To screen for proteases that pro-
mote myelination, we treated myelinating DRG cultures
(Saher et al., 2009) with protease inhibitors and quanti-
ﬁed the number of MBP-positive segments 2 weeks after
induction of myelination (Fig. 1A). Application of the
BACE1 inhibitor ‘‘b-secretase inhibitor IV’’ (2 lM)
almost completely blocked myelination compared with
control cultures (inhibitor 36.25 6 33.31; control 1889.83
6 356.36 P < 0.01) (Fig. 1A), without affecting the num-
ber of axon-associated Schwann cells (inhibitor 103.97 6
8.33; control 100 6 9.22; P 5 0.38) (Fig. 1B). However,
when we prepared co-cultures from BACE1 deﬁcient
mice, myelination was impaired but not completely
blocked (Supp. Info. Fig. 1). This supports a role of
BACE1 in myelination (Hu et al., 2006; Willem et al.,
2006) but also indicated the activity of additional pro-
teases that might compensate for BACE1. Treatment of
co-cultures with the ADAMs inhibitor GM6001 (1 lM),
which preferentially targets TACE and several matrix
metalloproteases (MMPs 1, 2, 8, 9), increased the num-
ber of MBP-positive segments 1.8-fold when compared
with DMSO-treated control cultures (inhibitor 3393.5 6
512.37; control 1889.83 6 356.36; P < 0.05) (Fig. 1A)
and moderately increased the number of axon-associated
Schwann cells (inhibitor 152.5 6 15.48; control 100 6
9.22; P < 0.01). Thus, processing by ADAMs proteases
such as TACE inhibits myelination, in line with recent
ﬁndings (La Marca et al., 2011).
Next, we examined the consequences of protease inhi-
bition on the processing of an N-terminally HA-tagged
NRG1 type III variant expressed in HEK293T cells.
Western blotting of protein lysates from cells expressing
full-length NRG1 type III (HA-NRG1
FL; Fig. 2A), using
an anti-HA antibody, revealed three major bands
(Fig. 1C). The two upper bands most likely represent dif-
ferentially glycosylated ‘‘immature’’ ( 110 kD) and
‘‘mature’’ forms ( 140 kD) of the full-length NRG1 type
III isoform. The protein with lower molecular weight
( 75 kD) was compatible with a cleavage product of full-
length NRG1 type III, when processed in the juxtamem-
brane stalk region. This ‘‘base line’’ processing of NRG1
type III was unaltered in the presence of BACE1 inhibi-
tor (Fig. 1C). However, overexpression of BACE1 dramat-
ically diminished full-length NRG1 type III and resulted
in the accumulation of processed NRG1 type III, which
was fully blocked by the addition of BACE1 inhibitor
(Fig. 1C). This suggests that proteases other than
BACE1 can process NRG1 type III in HEK293T cells.
In vitro, BACE1 can cleave a polypeptide that models the
stalk region of NRG1b1, thereby producing a peptide frag-
ment, in which the C-terminal amino acid sequence reads
‘‘Gly-Ile-Glu-Phe-COOH’’ (Hu et al., 2008). We generated
the corresponding ‘‘GIEF’’ variant (termed HA-NRG1
GIEF)
that was in addition N-terminally tagged with the HA epi-
tope, mimicking NRG1 type IIIb1a after BACE1 cleavage
(Fig. 2A). Expression of HA-NRG1
GIEF in HEK293T cells
produced one major band co-migrating with processed
NRG1 type III (Fig. 1C). Co-expression of BACE1 (Fig. 1C)
did not cause visible processing of HA-NRG1
GIEF.
To determine whether BACE1 cleavage of full-length
NRG1 type III produces the GIEF C-terminus, we used
an antibody directed against the C-terminal ‘‘GIEF’’ epi-
tope (Willem et al., unpublished). We clearly detected
this epitope in HA-NRG1
GIEF transfected cell lysates, in-
dependent of BACE1 activity (Fig. 1D). In contrast, the
GIEF epitope accumulated in HA-NRG1
FL lysates only
when BACE1 was co-expressed (Fig. 1D). This demon-
strates that BACE1 cleavage of NRG1 type III can occur
at the GIEF site; however, there is also processing of
NRG1 type III in HEK293T cells (by other proteases)
that produces distinct C-termini.
We next assessed the capacity of HA-NRG1
GIEF to
activate ErbB receptors in a two-cell split-TEV assay,
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of NRG1 ligands with their cognate ErbB receptors in
co-cultures of two separately transfected cell populations
(Wehr et al., 2006). Similar to HA-NRG1
FL (145.83 6
13.83 RLUs; P < 0.001), expression of HA-NRG1
GIEF
(180.08 6 23.97 RLUs; P < 0.001) signiﬁcantly induced
the dimerization of ErbB2 and ErbB3 receptors when
compared with mock transfected cells lacking the NRG1
ligand (33.11 6 6.36 RLUs) (Fig. 2B). Thus, HA-
NRG1
GIEF serves as a ligand for ErbB3 and activates
ErbB2/ErbB3 heterodimers.
These data demonstrate a stimulatory role of BACE1
during myelination, which most likely involves activation
of full-length NRG1 type III through proteolytic cleavage
in the stalk region. In contrast, TACE (La Marca et al.,
2011) and other ADAMs proteases may serve as negative
regulators of peripheral myelination. Therefore, we
focused our analysis on the functional consequences of
the interaction between NRG1 type III and BACE1.
In DRG-Schwann cell co-culture, lentiviral expression
of HA-NRG1
GIEF in sensory neurons dramatically
increased the number of MBP-positive myelin segments,
similar to HA-NRG1
FL, when compared with noninfected
controls (Fig. 2C). However, the large number of myelin-
ated segments impeded reliable quantiﬁcation. Sensory
neurons from NRG1 type III null mutants (CRD-
NRG12/2) are not myelinated when wildtype Schwann
cells are added (Fig. 2D), as reported previously
(Taveggia et al., 2005). Lentiviral expression of
HA-NRG1
GIEF in CRD-NRG12/2 sensory neurons fully
Fig. 1. Proteases serve as positive and negative regulators of myeli-
nation. (A) Pharmacological BACE1 inhibition blocks myelination in
DRG dissociated explant cultures, whereas inhibition of ADAMs pro-
motes myelination. Fluorescent imunostaining for MBP (green). Num-
bers of MBP-positive segments (mean 6 SEM) after 14 days in vitro
(DMSO, ADAMs inh n 5 3 cultures; BACE1 inh n 5 2 cultures; 2 cover-
slips/treatment; *P < 0.05, **P < 0.01). Scale bar, 200 lm. (B) Axonal
association of Schwann cells is not impaired upon BACE1 or ADAMs in-
hibition in DRG neuron dissociated explant cultures. Immunostaining
for axons (Tuj1; red) and counterstaining for nuclei (DAPI; blue) after 9 d
of protease inhibitor treatment. Representative axon bundles used for
quantiﬁcation are delineated. Numbers of axon-associated Schwann cells
(per bundle length in lm) are displayed as percentage 6 SEM relative to
DMSO treated controls (n 5 2 cultures; 3 coverslips/condition; 3 bundles/
coverslip; P 5 0.38, **P < 0.01). Scale bar, 20 lm. (C) Cleavage of full-
length (HA-NRG1
FL), but not ‘‘processed’’ NRG1 type III (HA-NRG1
GIEF)
by BACE1. Western blot of transfected HEK293T cell lysates probed with
an anti-HA antibody. Expression of BACE1 (1B) strongly reduced the
level of full-length HA-NRG1
FL (black arrowheads) and resulted in the
accumulation of a  75 kD N-terminal processing product (white arrow-
head), which corresponds in size to HA-NRG1
GIEF. HA-NRG1
FL process-
ing by BACE1 was blocked by BACE1 inhibitor treatment (1B/Bi).
Expression of BACE1 had no visible impact on HA-NRG1
GIEF levels.
Note that ‘‘base line’’ processing of HA-NRG1
FL (1Bi) was not affected by
BACE1 treatment. (D) BACE1 cleaves HA-NRG1
FL in the juxtamem-
brane ‘‘stalk’’ region. Western blot of transfected HEK293T cell lysates
probed with an antibody against the C-terminal peptide sequence
‘‘GIEF’’. Note that the C-terminal in GIEF epitope only accumulates in
HA-NRG1
FL lysates when BACE1 was coexpressed (1B). HA-NRG1
GIEF
lysates served as a positive control. The membrane was reprobed for
tubulin as a loading control. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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by HA-NRG1
FL (Fig. 2D).
These data collectively demonstrate that proteolytic
cleavage of NRG1 type III by BACE1 produces a trans-
membrane protein with type II topology that stimulates
Schwann cell myelination in culture. In contrast, the
C-terminal domain of NRG1 and the cytoplasmic tail are
not required to induce myelination.
Fig. 2. BACE1 cleavage in the ‘‘stalk’’ region produces a myelina-
tion-inducing NRG1 type III variant. (A) Domain structure of
HA-NRG1
FL and HA-NRG1
GIEF. BACE1 cleavage of HA-NRG1
FL is
indicated by scissors. Protein domains: EGF-like domain (green),
cystein-rich domain (purple/black), transmembrane domain (brown),
HA epitope tags (red). EC: extracellular; IC: intracellular. (B)
HA-NRG1
FL and HA-NRG1
GIEF induce heterodimerization of ErbB2
and ErbB3 receptors in a two-cell split-TEV assay as measured by a  5
fold increase in luciferase reporter activity compared with controls.
Results are displayed as relative luminescence units (RLUs) 6SD (n 5 6;
***P < 0.001). (C) HA-NRG1
FL and HA-NRG1
GIEF stimulate myelination
in DRG neuron-Schwann cell co-cultures. Immunostaining for MBP (red)
demonstrates a dramatic increase in the number of myelin segments
upon lentiviral expression of HA-NRG1
FL or HA-NRG1
GIEF in sensory
neurons compared with noninfected control cultures (ctrl) 7 days after
myelination induction. Scale bar, 50 lm. (D) Sensory neurons prepared
from NRG1 type III null mutants (CRD-NRG12/2) are not myelinated
14 days after induction of myelination. Myelination is restored in NRG1
type III-deﬁcient axons after lentiviral overexpression of HA-NRG1
FL or
HA-NRG1
GIEF as demonstrated by immunostaining for MBP (red).
Neuroﬁlament (NF) staining (green) reveals the normal maintenance of
sensory axons in mutant cultures. Scale bar, 50 lm. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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In Vivo
To deﬁne the role of BACE1-processed NRG1 type III
for myelination in vivo and to compare its function with
that of full-length NRG1 type III, we generated two
transgenic mouse lines that overexpress HA-NRG1
FL
and HA-NRG1
GIEF under control of the neuronal Thy1.2
promoter (Caroni, 1997) (Fig. 3A). By RT-PCR, both
transgenes were expressed already perinatally in brain
(data not shown) and spinal cord (Fig. 3B), i.e., before
myelination. Western blotting conﬁrmed HA-NRG1
FL
and HA-NRG1
GIEF protein in spinal cord (Fig. 3C),
presumably spinal motor neurons (Fig. 3D). Both NRG1
isoforms also accumulated on the surface of large DRG
sensory neurons (Fig. 3D). In the brain, transgene
Fig. 3. Neuronal overexpression of epitope-tagged NRG1 type III-
variants in transgenic mice. (A) Schematic drawing of the Thy1.2 cas-
sette used for neuronal expression of HA-NRG1
FL and HA-NRG1
GIEF
cDNAs (tg). XhoI, restriction site for subcloning; NotI/PvuI, restriction
sites for cassette release; exons Ia, Ib, II, IV, and locations of RT-PCR
primers used in (B) are indicated. (B) HA-NRG1
FL and HA-NRG1
GIEF
transgenes are expressed in spinal cord at the onset of peripheral mye-
lination. Transgene-speciﬁc RT-PCR of spinal cord cDNAs from trans-
genic and wildtype (wt) mice at P1. Ampliﬁcation of b-actin was used
as a positive control. (C) HA-NRG1
FL and HA-NRG1
GIEF proteins are
expressed in the spinal cord of transgenic mice. Western blot of spinal
cord protein lysates (40 lg) at 2 months of age probed with an anti-HA
antibody. Arrowheads mark full-length (  140 kD) and processed HA-
NRG1 type III (  70 kD) as well as a lower molecular weight protein
band (  45 kD), which most likely results from further NRG1 type III
processing. (D) Spinal cord motor neurons and sensory neurons express
HA-NRG1
FL and HA-NRG1
GIEF proteins at their plasma membrane.
Confocal images of spinal cord and DRG cross sections after immuno-
staining for the HA-epitope, neuroﬁlament 200 (NF), and peripherin
(Prph). White line marks the border between gray and white matter.
Scale bars, 50 lm. [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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GLIAexpression was prominent in cortical projection neurons,
but absent from interneurons and glia cells (Fig. 4A).
Interestingly, both HA-NRG1
FL and HA-NRG1
GIEF pref-
erentially accumulated in neuronal somata and den-
drites, including dendritic spines (Fig. 4B right panel),
whereas the expected axonal expression was not
pronounced (Fig. 4B left panel, arrowheads). Immunoe-
lectron microscopy demonstrated a co-localization of
HA-NRG1
FL with PSD95 in postsynaptic densities of
cortical synapses (Fig. 4C).
The level of neuronal NRG1 type III expression deter-
mines myelin sheath thickness of PNS axons (Michailov
et al., 2004). Thus, we addressed axonal expression of
NRG1 type III. We performed Western blots of tissue
lysates with an antibody directed against the common
C-terminus of NRG1 and probed wildtype mice at P12
and 2 months of age. This readily detected the expression
of full-length NRG1 and a proteolytically cleaved C-ter-
minal fragment (CTF) in spinal cord, but these proteins
were barely detectable in sciatic nerves (Fig. 5A; Supp.
Info. Fig. 2A). Using the same antibody, immunostaining
of spinal cord (Fig. 5A) revealed the patchy accumulation
of NRG1 on the surface of ventral horn motor neurons,
most likely at postsynaptic sites (Issa et al., 2010). In
contrast, this antibody revealed little NRG1 expression
on axonal cross sections of the sciatic nerve (Fig. 5A).
In these experiments, we used an antibody against Necl1
as a positive control for the detectability of axonal
membrane proteins (Supp. Info. Fig. 3A,B).
By probing for the HA epitope, we also detected trans-
gene-derived NRG1 type III in tissue lysates from
HA-NRG1
FL (Fig. 5B; Supp. Info. Fig. 2B) and
HA-NRG1
GIEF mice (Fig. 5C; Supp. Info. Fig. 2C). We
observed prominent transgene expression in the spinal
cord of both lines, but sciatic nerve expression was again
low in HA-NRG1
GIEF and barely detectable in
HA-NRG1
FL mice. Similar to the endogenous protein, im-
munostaining of the HA epitope revealed prominent
expression of both transgenes in spinal motor neurons,
but only a modest axonal surface expression in a subset
of sciatic nerve axons (Fig. 5B,C). Here, we detected
the HA-NRG1
GIEF variant by confocal microscopy in
Fig. 4. Expression of the epitope-tagged NRG1 type III-variants in
the brains of transgenic mice. (A) HA-NRG1
GIEF expression in the cor-
tex exclusively localizes to neurons. Confocal images of cortical layer V
immunostained for the HA-epitope and cell type-speciﬁc markers. HA-
NRG1
GIEF accumulates in a subset of NeuN-positive cortical neurons
but is absent from parvalbumin (Parv)-expressing interneurons and
Olig2-positive oligodendrocytes. Scale bars, 25 lm. (B) Confocal image
of a HA epitope-positive neocortical projection neuron from a HA-
NRG1
GIEF transgenic mouse at 4 months of age. HA-NRG1
GIEF is
expressed in the soma, axon (arrowheads), and proximal dendrites (left
panel), as well as dendritic spines (right panel; arrowheads). Scale
bars, 10 lm. (C) Electron micrograph of a cortical synapse (postsynapse
is to the lower right) after immunogold labeling using anti HA- (black
arrowhead, 10 nm gold) and anti-PSD95 antibodies (white arrowhead,
15 nm gold). The HA-NRG1
FL transgene preferentially localizes to the
PSD95-positive postsynaptic compartment. Scale bar, 100 nm.
[Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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GLIAvesicle-like structures of the axonal lumen, in addition to
its surface localization (Fig. 5D). Taken together, these
data suggest that axonal delivery of NRG1 type III is
severely restricted in vivo, and that the steady-state
level of mature NRG1 type III on the axonal surface is
regulated, at least in part, by limited transport.
Fig. 5. Limited axonal transport of NRG1 type III. (A) (left panel)
Endogenous full-length NRG1 (140 kD) and a C-terminal processing
product (  60 kD; arrowheads) are detected with an antibody against
the C-terminus of NRG1 (aNRG1 C-term) in wt spinal cord protein
lysates at P12, whereas corresponding sciatic nerve expression is virtu-
ally absent. (right panel) Endogenous NRG1 accumulates on the
plasma membrane of spinal cord motor neurons after immunostaining
with the aNRG1 C-term antibody. Nuclei are counterstained with DAPI
(blue). Corresponding NRG1 immunoreactivity is absent from the sci-
atic nerve. Sciatic nerve axons are marked by tubulin (Tuj1; red). (B,C)
(left panels) When probed with an anti HA-antibody (aHA), HA-NRG1
type III (140 kD) and two N-terminal processing products (  70 kD and
  45 kD; arrowheads) are present in spinal cord protein lysates from
HA-NRG1
FL transgenic mice at P12, but barely detectable in sciatic
nerve. Similarly, HA-NRG1
GIEF (  70 kD) and a smaller protein species
(  45 kD; arrowheads) are prominently expressed in spinal cord lysates
from HA-NRG1
GIEF mice, whereas sciatic nerve expression is low. (right
panels) Immunostaining for axons (neuroﬁlament 200, NF; red) and the
HA-epitope (green) reveals localization of HA-NRG1
FL and HA-
NRG1
GIEF at the surface of individual sciatic nerve axons (insets). Scale
bars, 10 lm. (D) Confocal images of an individual sciatic nerve axon in
cross section from an adult HA-NRG1
GIEF transgenic mouse. Immuno-
staining for neuroﬁlament 200 (NF; red) and the HA tag (green) reveals
expression of HA-NRG1
GIEF in vesicle-like structures (white arrow-
heads) and on the axonal surface (empty arrowheads). Scale bar,
2.5 lm. [Color ﬁgure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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GLIANRG1
GIEF Promotes Myelination In Vivo
To assess the capacity of the ‘‘preprocessed’’ GIEF-var-
iant to also promote myelination in vivo, we performed a
morphological analysis of sciatic nerves at 2 month of
age (Fig. 6A). In HA-NRG1
GIEF transgenic mice, periph-
eral myelin was signiﬁcantly thicker (g-ratio: 0.578 6
0.033) than myelin from age-matched controls (g-ratio:
0.661 6 0.009; P < 0.05), which is similar to hypermyeli-
nation found in HA-NRG1
FL transgenic mice (g-ratio:
0.558 6 0.027; P < 0.05) (Fig. 6B).
We note that HA-NRG1
GIEF stimulated physiological
myelin growth, without myelin pathology except for rare
tomaculae (not shown). Furthermore, the number of
myelinating (wt 159.33 6 16.75; HA-NRG1
GIEF 127 6
9.61; P 5 0.08) and nonmyelinating Schwann cells (wt 76
6 7.23; HA-NRG1
GIEF 87.67 6 8.41 P 5 0.18) was not sig-
niﬁcantly altered in adult HA-NRG1
GIEF transgenic mice
(Fig. 6C), demonstrating that the GIEF variant is not a
potent mitogen for Schwann cells. When we quantiﬁed
myelinated axons in sciatic nerves of HA-NRG1
GIEF
transgenic mice, their absolute number was not signiﬁ-
cantly different from controls (wt 4068.67 6 164.80; HA-
NRG1
GIEF 3963.67 6 49.65; P 5 0.29) (Fig. 6D), demon-
strating that chronic HA-NRG1
GIEF overexpression has no
adverse effects on axonal integrity.
We have previously reported that neuronal overexpres-
sion of full-length NRG1 type III causes hypermyelination
in the CNS (Brinkmann et al., 2008). To determine if oligo-
dendrocytes respond to neuronally overexpressed HA-
NRG1
GIEF, we analyzed g-ratios in the corpus callosum of
HA-NRG1
GIEF transgenic mice by electron microscopy. At
2 months of age, callosal ﬁbers were signiﬁcantly hyper-
myelinated (0.760 6 0.009) compared with wildtype (0.790
6 0.007; P < 0.05) (Fig. 6E), similar in extent to mice over-
expressing full-length HA-NRG1
FL (not shown).
Collectively, these data demonstrate that ‘‘prepro-
cessed’’ HA-NRG1
GIEF possesses all the features
required for axonal targeting of the protein and for stim-
ulating Schwann cells and oligodendrocytes to synthe-
size myelin.
Is Proteolytic Processing Required for
NRG1 Type III Signaling Activity?
To determine whether NRG1 signaling depends on
BACE1 activity, we analyzed transgenic mice with ele-
vated levels of full-length NRG1 type III in combination
with complete BACE1 deﬁciency. We conﬁrmed that sci-
atic nerves are hypomyelinated in BACE1 null mutants
(wt 0.661 6 0.009; BACE12/2 0.776 6 0.005; P < 0.01)
(Fig. 7A,B), but also challenged the system by additional
NRG1 type III overexpression. Remarkably, sciatic
nerves from BACE1 null mutants expressing full-length
transgenic mice after HA-NRG1
FL were clearly hyper-
myelinated (0.588 6 0.015; P < 0.01) (Fig. 7A,B). Thus,
BACE1 deﬁciency did not reduce the ability of HA-NRG1
FL
to promote myelination as evidenced by g-ratios that were
not signiﬁcantly different in NRG1
FL*BACE12/2 mutants
and HA-NRG1
FL transgenic mice (0.558 6 0.027; P 5 0.35)
(Fig. 7A,B).
In addition to myelination, NRG1 signaling is crit-
ically important for the expansion and survival of the
Schwann cell precursor pool during embryonic develop-
ment (Meyer and Birchmeier, 1995; Wolpowitz et al.,
2000). Thus, we addressed whether the loss of BACE1-
mediated processing of NRG1 affects Schwann cell num-
bers. When quantiﬁed at 2 months of age, the number of
myelinating Schwann cells in BACE1 mutants was
increased compared with wildtype (wt 159.33 6 16.75;
BACE12/2 206.25 61 0.21; P < 0.05), whereas nonmye-
linating Schwann cells were concomitantly decreased
(wt 76 6 7.23; Bace12/2 31.75 6 4.15; P < 0.01)
(Fig. 7C), such that the total number of Schwann cells
was unchanged. These data strongly suggest that
BACE1 is not critically required for the initial expansion
and survival of the Schwann cell precursor pool.
Finally, we monitored the processing of HA-NRG1
FL
in a BACE1 null mutant background. In the spinal cord
of HA-NRG1
FL transgenics, the relative ratio of full-
length/processed NRG1 type III was 0.92 6 0.13
(Fig. 7D). On the BACE1-null background, we found an
increased ratio, i.e., accumulation of full-length NRG1
type III and reduction of the processed isoform (2.99 6
0.44; P < 0.05). However, also BACE1 null mutants har-
bor about 50% processed transgene-derived NRG1 type
III in the spinal cord, but the responsible protease has
not been identiﬁed (Fig. 7D).
DISCUSSION
We have used novel NRG1 transgenic mouse lines to
directly prove the hypothesis that BACE1-mediated cleav-
age of NRG1 type III produces an axonal myelination sig-
nal (Willem et al., 2006). Moreover, we conﬁrm the hypoth-
esis that the juxtamembrane stalk region of full-length
NRG1 type III is the critical site for BACE1 processing
in vivo. Transgenic expression of a ‘‘preprocessed’’ NRG1
type III isoform (NRG1
GIEF) promotes myelination in vivo
and rescues the myelination defect when NRG1 type
III-deﬁcient sensory neurons are co-cultured with myelina-
tion competent Schwann cells. Thus, NRG1
GIEF provides
all necessary protein functions to stimulate the myelination
program of Schwann cells, implying that the C-terminal
domain of NRG1 type III is dispensable.
Interestingly, in the absence of BACE1, we found pro-
teolytic cleavage of the NRG1 type III stalk region to be
reduced but not completely abolished. Moreover, breeding
BACE1-deﬁcient mice to NRG1 type III transgenic mice
rescued peripheral hypomyelination and even produced
hypermyelination. Also, normal numbers of Schwann
cells in BACE1 mutants demonstrate that the NRG1 type
III dependent expansion of the Schwann cell precursor
pool is not markedly compromised. These data suggest
that either additional proteases participate in the process-
ing of NRG1 type III or that full-length NRG1 type III has
sufﬁcient signaling activity to promote the initial stages
of Schwann cell development and myelination.
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GLIAFig. 6. HA-NRG1
GIEF promotes hypermyelination in the PNS and
CNS of transgenic mice. (A) Sciatic nerve hypermyelination in HA-
NRG1
FL and HA-NRG1
GIEF transgenic mice. Methylenblue-Azure II stain-
ing for myelin on semithin sciatic nerve cross sections at 2 months of age.
Scale bar, 10 lm. (B) Quantiﬁcation of myelin sheath thickness by g-ratio
analysis. HA-NRG1
FL and HA-NRG1
GIEF transgenic mice exhibit signiﬁ-
cantly thicker myelin compared with wt (*P < 0.05). Bars represent mean
g-ratios 6 SEM (n 5 3; >100 axons/mouse). (C) The number of myelinated
and nonmyelinated Schwann cells is not changed in HA-NRG1
GIEF trans-
genic mice compared with wt at 2 months of age (n 5 3; mSchwann cells
P 5 0.08; nmSchwann cells P 5 0.18). Error bars, 6SEM. (D) The total
number of myelinated axons in sciatic nerves from HA-NRG1
GIEF trans-
genic mice at 2 months of age is unaltered (n 5 3e a c h ;P 5 0.29). Error
bars, 6SEM. (E) Electron micrographs of the corpus callosum at 2 months
of age. Scatter plot (upper panel) displays g-ratios as a function of axon
diameter. The average g-ratio (lower panel) in HA-NRG1
GIEF transgenic
mice is signiﬁcantly reduced when compared with wt (wt, n 5 3;
HA-NRG1
GIEF n 5 4; *P < 0.05). Error bars, 6SEM. Scale bar, 0.25 lm.
[Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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GLIAProteolytic Cleavage in the Stalk Region Produces
a Myelination-Inducing NRG1 Type III Variant
NRG1
GIEF restores myelination of NRG1 type III-deﬁ-
cient sensory neurons and promotes myelination in the
PNS and CNS of transgenic mice despite lacking the
‘‘classic’’ transmembrane domain and the C-terminal cyto-
plasmic tail. Thus, these protein domains are not essential
for correct axonal presentation by NRG1 type III and for
stimulation of glial ErbB receptors. Moreover, neuronal
Fig. 7. The myelination-promoting competence of NRG1 type III is
not compromised in the absence of BACE1. (A) Semithin sciatic nerve
cross sections stained for myelin at 2 months of age. Sciatic nerves
from BACE12/2 mutants are severely hypomyelinated and HA-
NRG1
FL transgenic nerves are hypermyelinated compared with wt.
Expression of the HA-NRG1
FL transgene in a BACE1 null background
restores myelination. Scale bar, 10 lm. (B) Quantiﬁcation of myelin
sheath thickness by g-ratio analysis. HA-NRG1
FL overexpression in
BACE12/2 mutants signiﬁcantly increases myelin sheath thickness
compared with BACE12/2 mutants (**P < 0.01) and even wt (**P <
0.01). Myelin sheath thickness in HA-NRG1
FL*BACE12/2 mutants is
not signiﬁcantly reduced compared with HA-NRG1
FL transgenic mice
(P 5 0.35). (n 5 3 per genotype, >100 axons/mouse). The scatter plot
(lower panel) illustrates that HA-NRG1
FL expression in BACE12/2
mice rescues the myelination deﬁcit of BACE1 mutants across all axon
diameters. (C) Myelinating Schwann cells (left panel) are increased and
nonmyelinating Schwann cells (right panel) decreased in adult
BACE12/2 mutants (n 5 4) compared with wt (n 5 3) at 2 months of
age (mean6SEM; *P < 0.05; **P < 0.01) (D) ‘‘Stalk’’ cleavage of NRG1
type III is reduced but not abolished in the absence of BACE1. Western
blot of spinal cord protein lysates from 2 months old mice probed with
an anti-HA antibody. Processed NRG1 type III ( 70 kD) is reduced,
whereas full-length NRG1 type III ( 140 kD) accumulates in HA-
NRG1
FL*BACE12/2 compound mutants compared with HA-NRG1
FL
transgenic mice. Membrane was reprobed for tubulin as a loading con-
trol. Densitometric quantiﬁcation demonstrates a signiﬁcant increase in
the relative signal ratio ( 140 kD/ 70 kD protein bands relative to
tubulin) in HA-NRG1
FL*BACE12/2 mice 6 SEM; *P < 0.05). [Color
ﬁgure can be viewed in the online issue, which is available at wileyonli-
nelibrary.com.]
214 VELANAC ET AL.
GLIA‘‘back signaling’’ of the CTF after cleavage (Bao et al. 2003;
Bao et al., 2004) appears dispensable for myelination.
NRG1
GIEF (derived from NRG1 type IIIb1a) closely
resembles the ‘‘sensory and motor neuron derived factor’’
SMDF (NRG1 type IIIb3), a natural splice variant of
NRG1 type III (Ho et al., 1995). In contrast to NRG1
GIEF,
neuronal overexpression of SMDF in transgenic mice did
not induce hypermyelination but potently stimulated pro-
liferation of nonmyelinating Schwann cells, resulting in
neuroﬁbroma-like neoplasia (Gomez-Sanchez et al., 2009).
This functional heterogeneity between NRG1
GIEF and
SMDF most likely resides in the distinct C-terminus of
SMDF, which may serve as an acylation-like post-transla-
tional modiﬁcation site (Cabedo et al., 2002), thereby
resulting in a tighter membrane-association of SMDF
(including its EGF-like domain) when compared with
NRG1
GIEF. Thus, SMDF may differentially stimulate glial
ErbB receptors and downstream signaling pathways.
Similar to SMDF, transgenic overexpression of a solu-
ble NRG1 type IIb3 variant (glial growth factor; GGF)
in myelinating Schwann cells causes glial hyperplasia,
demyelination, and onion bulb formation (Huijbregts et
al., 2003). Thus, chronic exposure to several NRG1b3
variants can exert adverse effects on nervous system in-
tegrity in vivo. In contrast, we show here that HA-
NRG1
GIEF (the b1a isoform) is a potent stimulator of
myelination without affecting Schwann cell numbers or
inducing major myelin abnormalities.
Limited Axonal Transport of NRG1 Type III
Because of the lack of suitable antibodies, the subcellular
localization of the N-terminal portion of NRG1 in the nerv-
ous system has been difﬁcult to address. Thus, our trans-
genic mice that express epitope-tagged NRG1 type III
variants represent novel tools to study the expression, proc-
essing, and subcellular targeting of NRG1 type III in vivo.
We demonstrate axonal surface localization of the N-termi-
nal domain of NRG1 type III and observe luminal expres-
sion of processed NRG1 type III, indicating axonal target-
ing via vesicular transport. Moreover, our data suggest
that axonal transport may be rate limiting for myelination,
providing a potential mechanism how the level of axonal
NRG1 type III is tightly regulated during myelination.
Several mechanisms dictate the differential distribu-
tion of membrane proteins in neurons, including polar-
ized delivery into the dendritic compartment followed by
internalization, transcytosis, and axonal targeting
(Winckler and Mellman, 2010). As NRG1 type III is
prominently targeted to the somatodendritic compart-
ment (Bare et al., 2011), we suggest that axonal trans-
port of NRG1 type III follows such an indirect pathway.
NRG1 Type III Serves as a Myelination Signal in
the Absence of BACE1 Processing
Hypomyelination of peripheral nerves in BACE1
mutants has been linked to impaired processing and
activation of NRG1 type III (Willem et al., 2006). We
provide direct evidence that BACE1 cleavage occurs in
the stalk region of full-length NRG1 type III, and that
BACE1-processed NRG1 type III (NRG1
GIEF) is a myeli-
nation signal. However, our ﬁndings suggest that
NRG1
GIEF represents only a fraction of all N-terminal
NRG1 fragments that we detect in transgenic mice
when probing for the N-terminal HA epitope. We con-
clude that cleavage of NRG1 type III by BACE1 and
other proteases produces several myelination-inducing
N-terminal NRG1 fragments with similar size but
slightly different C-termini. The activity of additional
proteases is further supported by our genetic gain-of-
function experiments that have identiﬁed an unexpected
independence of NRG1 type III signaling from BACE1
activity during myelination. Stalk cleavage of NRG1
type III is only modestly reduced in the absence of
BACE1, and simple breeding to NRG1 type III trans-
genic mice fully restores myelination in BACE1 null
mutants. This demonstrates that NRG1 type III is also
functionally active in the absence of BACE1. Functional
NRG1 signaling in the absence of BACE1 is further sup-
ported by normal number of Schwann cells in sciatic
nerves from BACE1 null mice.
We conclude that BACE1-mediated activation of
NRG1 is not required for the initial expansion and sur-
vival of the Schwann cell precursor pool during embry-
onic development, a process that critically depends on
NRG1 (Meyer and Birchmeier, 1995; Wolpowitz et al.,
2000). Although the total number of Schwann cells is
unchanged, we observed an increase in myelinating
Schwann cells and a concomitant reduction of nonmyeli-
nating Schwann cells in BACE1 deﬁcient mice. Thus,
BACE1 may regulate Schwann cell fate. Whether this
involves NRG1 processing (or other targets) requires
further investigation.
Disruption of NRG1 in motor neurons during adult-
hood impairs axonal regeneration and remyelination af-
ter nerve injury (Fricker et al., 2011). Although remyeli-
nation after nerve injury was also reduced in BACE1
null mutants (Hu et al., 2008), axonal regeneration was
enhanced (Farah et al., 2011), further supporting the hy-
pothesis that NRG1 signaling in the PNS is, at least in
part, independent from BACE1.
This unexpected independence of NRG1 type III sig-
naling from BACE1 function could be explained either
by sufﬁcient signaling activity of full-length NRG1 type
III or by the activity of additional proteases that also
process NRG1 type III (or by a combination of both).
Noncleavable variants of TGF-beta can activate the EGF
(ErbB1) receptor (Brachmann et al., 1989; Wong et al.,
1989) and plasma membrane preparations harboring
human NRG1 type I stimulate ErbB2 phoshorylation
and DNA synthesis in cultured cells (Aguilar and Sla-
mon, 2001). This supports the idea that also full-length
ligands for ErbB receptors are functionally active.
Compensating for BACE1 could be ADAMs metallo-
proteases that were shown to process NRG1 type I-var-
iants in vitro, including ADAM8 (Guaiquil et al., 2010),
ADAM10 (Luo et al., 2011), ADAM17/TACE (Horiuchi
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GLIAet al., 2005; Montero et al., 2000), and ADAM19/b-mel-
trin (Shirakabe et al., 2001; Yokozeki et al., 2007).
Because TACE has been identiﬁed as a negative regulator
of myelination (La Marca et al., 2011), it may inactivate
rather than activate NRG1. Similarly, pharmacological
inactivation of ADAMs proteases (our study) or matrix met-
alloproteinase-28 (Werner et al., 2008) stimulates myelina-
tion in vitro. Therefore, the exact function of other ADAMs
metalloproteinases in myelination and their role in NRG1
type III processing (including shedding of the EGF-like do-
main) will be an important subject of future research.
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